PANGEA
Phase 1/2 Recruiting
104 enrolled
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Phase 1/2 Terminated
33 enrolled 22 charts
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Phase 1/2 Recruiting
20 enrolled
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Phase 1/2 Completed
24 enrolled 8 charts
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase 1/2 Terminated
21 enrolled 8 charts
A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer
Phase 1/2 Terminated
5 enrolled
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Phase 1/2 Completed
27 enrolled 12 charts
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Phase 1/2 Completed
81 enrolled 19 charts
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Phase 1/2 Completed
32 enrolled 13 charts
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Phase 1/2 Completed
38 enrolled 12 charts
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Phase 1/2 Terminated
27 enrolled 18 charts
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Phase 1/2 Completed
81 enrolled 14 charts
Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
Phase 1/2 Completed
41 enrolled
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
Phase 1/2 Terminated
22 enrolled
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Phase 1/2 Completed
11 enrolled 16 charts
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
Phase 1/2 Completed
49 enrolled 8 charts
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
Phase 1/2 Completed
46 enrolled 15 charts
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Phase 1/2 Completed
32 enrolled 14 charts
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
Phase 1/2 Completed
64 enrolled 11 charts
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Phase 1/2 Completed
15 enrolled 16 charts
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
Phase 1/2 Terminated
8 enrolled 7 charts
TARGET
Phase 1/2 Completed
44 enrolled
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Completed
53 enrolled 10 charts
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
Phase 1/2 Terminated
10 enrolled
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Phase 1/2 Completed
11 enrolled 6 charts
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Phase 1/2 Completed
62 enrolled 15 charts
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Phase 1/2 Completed
21 enrolled 8 charts
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
Phase 1/2 Withdrawn
Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
Phase 1/2 Completed
17 enrolled 7 charts
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
Phase 1/2 Withdrawn
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
Phase 1/2 Withdrawn
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Phase 1/2 Completed
94 enrolled 7 charts
Celecoxib and Erlotinib in Treating Patients With Liver Cancer
Phase 1/2 Withdrawn
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Phase 1/2 Completed
Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Phase 1/2 Completed
42 enrolled